Nevertheless, we are aware that, according to the guidelines, the newborn screening test should not be used to discriminate between profound and partial BD, despite the above-mentioned pitfalls in serum biotinidase assay and the potential informative role of molecular analysis in unambiguously determining “an individual’s enzyme deficient status” if a molecular variant database has been established [5]. The gene discussed is BTD; the disease is Behcet disease.